Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

Sandrock left Biogen after 23 years at the company as the ... for Friedreich's ataxia and other undisclosed diseases. On the plus side, Voyager agreed a $630 million alliance with Pfizer in ...

and is thought to have the greatest commercial potential of the two with a chance of $1 billion-plus sales at peak. Qalsody, meanwhile, has been tipped to make around $300 million. Biogen acquired ...

Twenty-five years ago, the bestseller “The Tipping Point” turned Malcolm Gladwell into a household name. Describing “the critical mass, the threshold, the boiling point,” Gladwell illustrates ...

Bristol Myers Squibb today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi® (lisocabtagene maraleucel; ...

December 05, 2024--GeneDx today announced Biogen, Praxis Precision Medicines ... disclosed a new position in Healthcare Realty Trust. Plus, Paysafe, Getty Images, and GeneDx.

Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The European Commission has requested its medicines regulator to consider safety information on Eisai and Biogen's ...

Biogen (NASDAQ:BIIB) and Eisai (OTCPK:ESALF) are expected to face another delay in launching their new Alzheimer's drug, lecanemab, in the EU after the European Commission on Friday asked the ...

In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other S&P 500 stocks. 2024 was a memorable year for the broad market index, which posted a gain ...